Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gepotidacin tissue penetration in prostate and tonsils
NCT04484740Phase 1Completed
- Sponsor
- Inserm
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of gepotidacin in prostatitis and Pharyngeal gonorrhea (PGC), sponsored by Inserm. Primary endpoints: Area Under the Concentration-Time Curve from Zero to Last Observed Concentration at 48 hours, Area Under the Concentration-Time Curve from Zero to Infinity at 48 hours and 3 more. Started Jan 2021; status: completed.
02
Drugs
gepotidacin
03
Conditions
prostatitisPharyngeal gonorrhea (PGC)
Beyond the preview
Go deeper on NCT04484740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484740.